ISSCA to Launch Regenerative Medicine Studies Program in Collaboration with Medicel Chile
International Society for Stem Cell Application ISSCA to Launch Postgraduate Studies Program in Stem Cell Therapies and Regenerative Medicine in Collaboration with Medicel Chile
ISSCA and Medicel, Inc. have announced plans to launch a post-graduate studies program in stem cell and regenerative medicine, to be conducted in Santiago Chile February 2021.
MIAMI, July 20 , 2020— The international Society for Stem Cell Application ISSCA and Medicel Chile have announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2020.
The program will include Seven days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Medicel’s Chief Scientific Officer and Other leading Scientists will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.
Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting
The graduate course will be scheduled 3 times during 2020 starting February 23rd
“ Our end goal in Launching this Fellowship program is to help physicians that are looking for really advanced and formal training in Cellular Therapies and Regenerative Medicine — We want to provide them the necessary skills and in depth specialization that is lacking in our smaller point of care programs ,” noted Benito Novas ISSCA Public Relations Director
To learn more about the February 2020 certification event in Santiago, or any of the other upcoming certification courses around the world, visit the ISSCA website.
About the International Society for Stem Cells Applications (ISSCA)
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine.
Incorporated and Trademarked in the United States of America as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts. ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit the ISSCA’s website or send an email to info@stemcellsgroup.com www.stemcellsgroup.com
About Medicel Chile
Medicel Chile is one of the premiere regenerative medicine treatment centers in the country of Chile, conveniently located in Santiago de Chile, one of the largest metropolitan areas in Latin America. Medicel carries with it a reputation as one of the most scientifically advanced and professional regenerative medicine Laboratories in Chile, and this is in no small part due to its highly-qualified team of scientists and medical professionals and advisers, who research tirelessly to head new breakthroughs in the fields of cellular therapy and cryopreservation, which is the freezing of a stem cell sample to ensure its longevity and freshness, should the patient receiving the service ever wish to use their frozen cells for some future malady.
- Published in Press Releases
Stem Cell Center Network in Lisbon Portugal
The Stem Cell Center Network ( a Division of Global Stem Cells Group ) is an international network of regenerative medicine practitioners . Dedicated to promoting the research and development of the field of regenerative medicine, and strives to bring patients cutting-edge treatments that make use of the ever-growing list of benefits that regenerative medicine carry. This week, in a part of their effort to expand their foothold in medical communities around the world, the Stem Cell Center Network has announced the opening of a new training facility in Lisbon, Portugal.
Over the years, the Stem Cell Center Network has sought out to aggressively expand and roll out new membership opportunities, programs, events, and more– an effort that has been redoubled in the last five years. As a result, we have added members that practice regenerative medicine under our banner in over twenty five countries spread across five continents.
The new Portuguese center will be located in the clinic of Dr. Hugo Madeiras, a highly-accredited physician and scientist who will preside over the facility as the Global Stem Cells Group chief representative in Portugal. As the CEO and founder of the Clinic of Advanced Implantology, he focuses exclusively on implantology, esthetics, and digital workflows, and collaborates with over twenty doctors and seventy resources in total. He is also the clinical collaborator for the Straumann Group, a faculty which includes product testing, lecturing, and the creation and delivery of educational content.
Dr. Madeiras graduated from the Instituto Superior de Ciências da Saúde Egas Moniz in Medicine in 2007, and with a Master in Oral Rehabilitation from CESPU in 2009. With his over ten year of experience in the field, he acts as a speaker at several national and international congresses that go over developments and new treatment protocols in the field of dentistry.
“This new center will help in bringing regenerative medicine to the people of Lisbon. It will treat patients with a wide variety of different diseases, but with a special emphasis on Aesthetic Medicine,” Said Benito Novas CEO of the Global Stem Cells Group about the new Stem Cell Center Network partnership, “This new facility will be at the top of the line, a place where Portuguese doctors can come to learn about regenerative medicine protocols, and the advancements that have been made in the field. I am incredibly excited to be working in partnership with Global Stem Cells Group , and look forward to many years as a program leader here in Portugal,”
Stem Cell Center Network plans for the clinic to open in September 2020– and with that date looming closer and closer with each passing week, a date has also been agreed upon for the clinic’s inaugural training– indeed, it will be a place for doctors around the country to convene and learn, share, and research the complexities and applications of regenerative medicine. Barring any extenuating circumstances, the next first Regenerative Medicine Certification Training in the Portuguese clinic will take place on September 25 & 26th, 2020– just weeks after its formal opening. With only 10 spots available, applicants are encouraged to sign up soon for the hands-on training course.
To sign up today, visit: https://issca.us
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
- Published in Press Releases
Global Stem Cells Group has Announced an Agreement with Rokit Healthcare
Global Stem Cells Group announces an agreement with the South Korean biotechnology giant known as Rokit Healthcare to represent the company’s technology in the Latin American market.
The Global Stem Cells Group (GSCG) a world leader in Regenerative Medicine Technologies has signed an agreement with South Korean-based Rokit Healthcare, an esteemed bioprinter manufacturer that is committed to advancing the field of regenerative medicine and bettering the quality of life of people around the world.
The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Growth factors are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an ‘organ regenerator’– it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.
The process of 3D bioprinting human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in regenerative medicine research and tissue engineering is mimicking the micro and macro environment of human tissues. In response to this challenge, advances in additive manufacturing have inspired scientists in Korea to develop novel bioprinting technology, for human tissues and organs
With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing– and Global Stem Cells Group, in an effort make this revolutionary technology available to patients, has forged an agreement with Rokit Healthcare to promote, and distribute the company’s technology in Latin America-
The Invivo 4D Printer is Rokit Healthcare’s flagship product, and it is one that revolutionizes the application of regenerative medicine and growth factor-based therapies. creating a solution for personalized and improved patient care. By leveraging a combination of 3D and bioprinting technologies, it can better distribute a patient’s autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.
“We’re extremely excited about this new opportunity and look forward to working with Rokit,” Says Benito Novas, CEO of the Global Stem Cells Group, “The Invivo 4D Printer is in a position to turn the practice of regenerative medicine onto its head, and we are planning on creating a training center in Cancun, Mexico exclusively to showcase and instruct other physicians in this cutting-edge technology,”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for regenerative medicine solutions that adhere to the highest medical standards.
About ROKIT :
ROKIT Healthcare is a global healthcare company that is committed to providing an effective and autologous organ regeneration platform. In order to undertake this daunting task, the company uses proprietary biofabrication technologies that show promise in treating several types of diseases in the field of regenerative medicine. Through the proliferation of 4D bioprinting technology, autologous stem cell technologies, ROKIT Healthcare believes that supplying an avenue for organ regeneration will drastically change the way that everyday people trust and manage their own body.
- Published in Press Releases
ISSCA Announces New Buenos Aires Symposium
The International Society of Stem Cell Applications (ISSCA) has hereby announced the date of it’s seventh Symposium of Regenerative Medicine. As before, the organization hopes to bring together a network of regenerative medicine practitioners from all over the world to foster a growth of knowledge among them. It will go over a wide range of topics related to regenerative medicine, chiefly among them will be the response of all levels of regenerative medicine research and practice in the COVID-19 pandemic, as well as what the future looks like for the field as a result of it. In addition to this, the symposium will also cover breakthroughs in the field, new treatment options and technological developments that are now available to both doctors and patients.
Cellular Therapies During and After the Pandemic
Cellular therapies have been an invaluable asset in managing the largest pandemic in modern history. This has been evidenced by the use of Mesenchymal cells, along with other growth factors and types of cells, to treat respiratory failure and manage some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials.
We are living in a unique time for regenerative medicine, as advancements are being made month after month, year after year at a rapid, exponential rate. Keeping track of the latest advancements in this research and development, and the medical protocols that occur as a result, is critical to safeguarding lives all over the world. Every medical society’s purpose is, primarily, to promote the growth of both their members and the field that they operate in. The International Society for Stem Cell Applications (ISSCA), strives to do just that. In the interest of designing the future of cellular therapies in a post-pandemic world, ISSCA invites pioneers of the field from around the world to form and share in a platform of experiences, knowledge, and progress.
Stem Cells Group to Host Regenerative Medicine Symposium in Buenos Aires, Argentina November 28th
After a period of silence brought about by the global COVID-19 pandemic, the Global Stem Cells Group (GSCG) is prepared to begin bringing medical professionals together by hosting a Regenerative Medicine Symposium in Buenos Aires, Argentina. The Symposium will take place at the Hotel Panamericano, Buenos Aires, on the 28th of November.
The Buenos Aires symposium will feature a wide variety of educational resources, including lectures and demonstrations, as well as product information. All of this is aimed at doctors that are looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to impart the latest information on the newest compounds in the allogeneic stem cell market, including exosomes, amniotic fluid compounds, and umbilical cord blood products. Allogeneic compounds have steadily been increasing in popularity within the field of regenerative medicine, and this is due to their increased safety and treatment efficacy as research has evolved. With this in mind, GSCG representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their own practices.
ISSCA CEO Benito Novas had this to say about the upcoming event: “We’ve barely even scratched the surface of potential for regenerative medicine, which is why it’s so important that we collectively gather and learn about what we’ve done thus far. This is a South
American congress that will witness some of the greatest regenerative doctors of our time
giving once-in-a-lifetime addresses to those in attendance.”
Among these speakers are Drs. Damian Siano, Silvina Pastrana, and Maritza Novas. Dr. Siano will look specifically at sports injuries, and draw on his experience as a sports medicine specialist aiding professional athletes in the world today. Dr. Pastrana, the Medical Director of the Buenos Aires Stem Cells Center, will speak about how stem cells can help to assuage aesthetic conditions. Dr. Novas, an ISSCA Fellow in Cell Therapy and Tissue Engineering, will look at the fundamentals of stem cell biology and their clinical applications. She will cover a broad range of topics concerning MSCs during their transition from bench-side to bedside.
In addition to the wide array of educational sessions offered, the Buenos Aires symposium will also provide a wide array networking and social opportunities for those physicians in attendance. To learn more about ISSCA’s upcoming Buenos Aires Symposium, or to register for the event, visit us at: https://www.issca.us/
About ISSCA
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
- Published in Press Releases
GLOBAL STEM CELLS GROUP ANNOUNCES THE LAUNCH OF ITS NEW DIVISION “VITA NOVAS”
A Step towards the Actualization of Regenerative Medicine
The Global Stem Cells Group takes another luminary step by launching its new company VITA NOVAS in the field of Regenerative medicine. Vita Novas is a mobile IV infusion company that provides in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases. Under the banner of GSCG, Vita Novas is ready to launch in 26 countries in the first year of its inception.
Having the cushion of an already established worldwide network and 10 years of experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation of quality, innovation, and professionalism. The VITA NOVAS’ program delivers micronutrients and stimulating biological products like Exosomes and Mesenchymal Stem Cells intravenously, guaranteeing an effective way for the ingredients to become immediately available to the cells. This greatly decreases the time it takes for the medication or supplements to take effect. Patient-centred carved out packages The Shield, the Fighter, and the Lightening are delivered on-demand to homes, offices, or hotels administered by certified healthcare professionals.
Believing on the percept of Prevent-Protect-Thrive, VITA NOVAS aspires to set standards in the industry, and committed to ensure in-home, and personalized patient service; keeping them away from hospitals and emergencies. VITA NOVAS offers infusion packages, mixed with essential fluids, electrolytes, vitamins, and antioxidants as a powerful cocktail to stimulate the immune system and help bolster it to assist in fighting infections and diseases. In-line with the evolved life pattern of social distancing, the process of treatment at VITA NOVAS culminates as:
Select your Service Area
Schedule a video consultation with our local doctors to discuss your possible treatment plan
Receive the treatment at home
“We have combined elements of Tele-health with cellular therapy, IV wellness infusions, and a direct-to-consumer model intending to capitalize on the burgeoning market for medical services at the patient’s’ place of residence, due to convenience and social distancing practices,” explains Benito Novas , CEO of VITA NOVAS.
The secret behind the VITA NOVAS program is the provision of assistance and prime incentives to medical professionals. Once a physician joins the network, the company provides training and support that they will need in order to set-up run, and market their practices. They enjoy geography and specialization exclusively as well as a strong network of patients referrals, increased revenues, and conduct consultations from home.
Global Stem Cells Group, with golden track record and experience of a decade, is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2010 by Benito Novas, the company combines dedicated researchers, physicians, patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading-edge Regenerative Medicine treatments. Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology, while adhering to the highest medical standards.
VITA NOVAS can help, to find your service area, please visit: www.vitanovas.net
To know more about the company , visit www.stemcellsgroup.com
- Published in Press Releases
ISSCA to Conduct First Hands On Regenerative Medicine Training after Global Pandemic
he COVID19 pandemic has brought about a ‘new normal’ of social-distancing, closed businesses and self-isolation. After several months of inactivity brought about by this virus and the period of self-isolation, the International Society for Stem Cell Application is ready to begin the process of resuming our schedule of training courses,
Florida (PRUnderground) May 19th, 2020
Now, more than ever, interest in the immune system and its health has breached our collective consciousness, both phycicians and scientist are turning to regenerative medicine as a way to strengthen it. Recent breakthroughs in the field have led to a newly devised program– one with a proprietary protocol for strengthening the immune system, furthering a person’s ability to fight and prevent disease.
This inaugural training will take place in Washington over the course of two days, during which we will be training a group of five doctors in the latest regenerative medicine techniques. We will go over our traditional program providing physicians with all of the tools they will need to begin incorporating regenerative medicine into their own practice
The International Society for Stem Cell Application is an independent, non-profit organization whose objective is to become the gold standard of regenerative medicine. It accomplishes this through hosting conferences and specialized certification courses, publishing and sharing clinical research, and setting protocols in the field of regenerative medicine. Through this partnership, we are seeking to spread knowledge on the current applications of cellular therapies by building a platform for doctors to discuss and debate the newest advancements in the field. These conferences have been held in dozens of countries, and work to create a global network of regenerative medicine researchers and practitioners.
If you’d like to know more information about our program, or the courses that we offer around the world, please check out by visiting our website at: www.issca.us
About International Society for Stem Cells Applications
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative
medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
- Published in Press Releases
GLOBAL STEM CELLS GROUP will host ISSCA Regenerative Medicine Training
After several months of silence due to the mandatory shutdown in place, the training division of Global Stem Cells Group –known as ISSCA Training– has officially announced the reopening of its regularly scheduled training dates Around the world
Miami, FL (PRUnderground) May 20th, 2020
“The future’s looking bright for our Regenerative MedicineTraining program, we’ve taken our course and updated it, reinforcing it with new information and quality protocols that’ll help doctors and their patients manage this ‘new normal’ as well as they can, and we’re very excited to be able to be bringing this new information to physicians around the world– but we’ve decided to start small for now, with the reinstatement of our headquarters’ operations,” — Benito Novas, CEO
Because of the growing interest in the industry , ISSCA Regenerative MedicineTraining has updated its program with new protocols focused on the optimization of the body at the cellular level. Notably, their upcoming June course will also include live practice patients in the treatments of autologous cell therapy, which includes PRP, adipose-derived stem cells, bone-marrow derived stem cells, exosomes, Umbilical Cord Blood Cells, and other novel techniques.
Stem Cell Training is a company that seeks to instruct medical professionals around the world on regenerative medicine techniques. They do this by sharing breakthrough scientific research on stem cell therapy and treatment, as well as developing and offering courses, seminars, and workshops based on this research.
About the Global Stem Cells Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2010, the company combines dedicated researchers, physicians ,patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge Regenerative Medicine treatments.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology
- Published in Press Releases
Global Stem Cells Group Announces Launch of Vita Novas In-Home IV Infusion Service
Its no secret that a quality IV infusion can boost health and energy. Vita Novas makes this more simple than ever performing IV services than revitalize the body and help it regenerate, right at home.
Miami , Florida (PRUnderground) May 20th, 2020
The interest in boosting the immune system in a safe and effective way is a topic on more minds than ever. In exciting news, Global Stems Group has announced the launch of a new company, Vita Novas who make this both simple and dependable. Vita Novas offers an IV infusion packages are a mix of stem cells, essential fluids, electrolytes, vitamins and antioxidants as a preventive solution for having an optimal immune system. This IV infusion is delivered at home, in an office, or at a hotel, by certified healthcare professionals. With the global pandemic shutting doors of physicians for elective and health-enhancing non-vital procedures going to get IV treatments in most communities is difficult, if not impossible. Vita Novas is opening the doors for these life-enhancing treatments to be accesses in an easy and convenient way.
“The demand for preventive health services using IV infusion is greater than ever,” commented Benito Novas, CEO of the company. “What we are doing, by offering these at home and offices, is not just making things more convenient but also following social distancing requirements. Its truly making the right thing available at the right time and place.”
Vita Novas provides a teleconsultation with a Doctor to determine what meets a patient’s needs best. Three different vitamin and nutrient vitamin infusion packages are available.
The Lighting Package consists of two sessions of IV administration of vitamins (Vitamin C, B-Complex vitamins, and trace minerals), with a patient follow up recommending dietary changes and oral supplements to maintain good health.
The Shield Package is three sessions of IV administered (high dose Vitamin C, Methylcobalamin, Zinc sulphate, Glutathione and five billion flow exosomes). This has been shown have a powerful effect in regulating regenerative processes in the body and increase cell to cell communication. This has been used to treat COVID-19 patients with exciting results, something clearly at the front of people’s minds of all ages and lifestyles.
The Fighter Packages is the platinum offer from Vita Novas. This combines IV administration of high dose micronutrients (amino acids, glutathione), vitamins (B-Complex, methylcobalamin, Folic Acid, Vitamin C), and trace minerals (zinc, copper, magnesium) along with 30 million live stem cells in 5 sessions. This can modulate immunity and assist in the regeneration process of damaged or infected tissue in a very dramatic way.
Vita Novas is currently positioned to be able to launch the program in ten different countries with the number rising to over 25 within six months. The near and far future are bright for the company and its potentially life-changing services.
About the Global Stem Cells Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2010, the company combines dedicated researchers, physicians ,patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge Regenerative Medicine treatments.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology
- Published in Press Releases
Bogota Course Will Share the Latest in Stem Cell Treatment Protocols
The two-day certification program is sponsored by ISSCA, will feature three topics new to the group’s Colombian training circuit
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a global leader in stem cells research, applications, and education, has announced their latest certification program to be held in Bogota, Colombia on March 13-14, 2020.
The Stem Cells Certification course will feature a number of educational and hands-on sessions designed to give physicians the tools needed to integrate regenerative treatments into their practices. Registration for the two-day course is limited to eight participants to allow for intensive training and interaction.
During the two-day training, ISSCA faculty will share the latest stem cell protocols, including how to harvest and process stem cells derived from Stromal Vascular Faction (SVF) tissue and bone marrow.
ISSCA faculty will additionally introduce three new protocols never before covered in past courses held in Colombia. The new curriculum includes clinical applications of allogeneic stem cells; using GCell technology, a device that can process SVF without enzymatic compounds; and an introduction to NK cell protocols, the newest regenerative medicine treatment to fight cancer.
“Our two-day training in Bogota will provide physicians with an invaluable opportunity to receive intensive hands-on training and education in some of today’s most effective and cutting-edge stem cells protocols,” said Benito Novas, ISSCA VP of Public Relations. “Physicians will learn from global leaders in the stem cells industry and be able to take practical application strategies back with them to integrate into their own practices to help patients suffering from degenerative diseases.”To learn more about the ISSCA, visit www.issca.us. More information about the Bogota certification course can be found at http://cursocelulasmadre.com/entrenamiento-bogota-programa/
- Published in Press Releases
Mexico City Medical Congress to Showcase the Global Stem Cells Group’s Latest Innovations
The group is sponsoring the event, which will attract physicians from across the globe with an interest in longevity and anti-aging medicine
MIAMI LAKES, Florida— The Global Stem Cells Group (GSCG) is set to sponsor the XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad (World Conference of Anti-Aging and Longevity Medicine) to be held in Mexico City, Mexico on February 16-18, 2020.
The medical congress is expected to attract over 450 physicians and researchers from across the world interested in anti-aging and longevity practices and medical innovations. Over 30 speakers are slated to share information with attendees on a wide range of topics on how to lead a long, healthy life and improve longevity.
The GSCG is set to share a number of its latest innovations with congress attendees, including its newly released GCell technology device. This cutting-edge tool utilizes micrograft technology to harness the natural and powerful restorative capabilities of adipose tissues. Because it is FDA compliant, the device allows physicians across the globe to continue practicing adult stem cells-based procedures.
Additional benefits of GCell technology include shorter treatment times, delivering in-office treatments in around 30 minutes with local anesthesia, as well as less fat collection compared to existing treatments (15 mL versus 50 mL). GCell technology holds exciting implications across a range of medical specialties, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.
In addition to its GCell technology, the GSCG will also feature its newest line of stem cells products derived from first-tissue exosomes. Cellgenic Flow Exosomes utilizes the latest science and research available in cellular therapies to deliver a non-surgical approach to creating regenerative responses in a broad range of treatments. The product utilizes exosomes, which replicate the signals given out by stem cells, versus actual stem cells. Exosomes play a pivotal role in cell-to-cell communication and are involved in a wide range of physiological processes. These particles transfer critical bioactive molecules such as proteins, mRNA, and miRNA between cells and regulate gene expression in recipient cells.
“The XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad is one of the world’s premier events connecting physicians and researchers with today’s most innovative treatments and technologies utilizing regenerative medicine,” said Benito Novas, CEO of the GSCG. “As a worldwide leader in training, education, and innovative products in the field of regenerative medicine, the GSCG is pleased to sponsor this congress and share its exciting new portfolio of products with physicians from across the world.”
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit http://www.stemcellsgroup.com/
- Published in Press Releases